This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions

Example ClinicalUseDefinition/example-indication (Narrative)

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: No defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile ClinicalUseDefinition.

Generated Narrative: ClinicalUseDefinition

Resource ClinicalUseDefinition "example-indication"

StructureDefinition Work Group: brr

type: indication

subject: MedicinalProductDefinition/example



*Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)


*Recurrent (diseasestatus#Recurrent)


*PRYLX (intendedeffect#PRYLX)


type: person

membership: definitional


*age-range (characteristic#age-range)18-? afalse



Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.